BACKGROUND: Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) coactivates multiple transcription factors and regulates several metabolic processes. In this study, we focused on the roles of PGC-1α in the apoptosis of endometrial cancer HEC-1A cells. MATERIALS AND METHODS: PGC-1a expression in the HEC-1A cells was detected with real-time polymerase chain reaction and Western blot. Small interfering RNA directed against PGC-1α was designed and synthesized, and RNA interference technology was used to knock down PGC-1α mRNA and protein expression. Cell apoptosis, cell cycle, and mitochondrial membrane potential were then analyzed using flow cytometry. The expression of apoptotic proteins, Bcl-2 and Bax, was detected with Western blot. RESULTS: The specific downregulation of PGC-1α expression in the HEC-1A cells increased their apoptosis through the mitochondrial apoptotic pathway by reducing the expression of Bcl-2 and increasing the expression of Bax. CONCLUSION: These results suggest that PGC-1α influences the apoptosis of HEC-1A cells and also provides a molecular basis for further investigation of the apoptotic mechanism in human endometrial cancer.
BACKGROUND:Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) coactivates multiple transcription factors and regulates several metabolic processes. In this study, we focused on the roles of PGC-1α in the apoptosis of endometrial cancerHEC-1A cells. MATERIALS AND METHODS:PGC-1a expression in the HEC-1A cells was detected with real-time polymerase chain reaction and Western blot. Small interfering RNA directed against PGC-1α was designed and synthesized, and RNA interference technology was used to knock down PGC-1α mRNA and protein expression. Cell apoptosis, cell cycle, and mitochondrial membrane potential were then analyzed using flow cytometry. The expression of apoptotic proteins, Bcl-2 and Bax, was detected with Western blot. RESULTS: The specific downregulation of PGC-1α expression in the HEC-1A cells increased their apoptosis through the mitochondrial apoptotic pathway by reducing the expression of Bcl-2 and increasing the expression of Bax. CONCLUSION: These results suggest that PGC-1α influences the apoptosis of HEC-1A cells and also provides a molecular basis for further investigation of the apoptotic mechanism in humanendometrial cancer.
Entities:
Keywords:
Bax; Bcl-2; PGC-1α; apoptosis; endometrial cancer
Endometrial cancer is one of the three major malignant tumors of the female reproductive
system. In recent years, the incidence of endometrial cancer has increased, and it
ranked sixth among new cases of female cancer throughout the world in 2012.1 Increasing research interest is being
directed toward tumor cell apoptosis, and studies of endometrial cancer cell apoptosis
can provide insight into the mechanism of endometrial cancer development and provide new
directions for its clinical treatment.Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) is
a member of the peroxisome proliferator-activated receptor gamma coactivator-1 family
and is the transcriptional coactivator of peroxisome proliferator-activated receptor
gamma. PGC-1α displays tissue-specific expression and is more strongly expressed
in tissues that are rich in mitochondria or have a high energy demand. It plays an
important role in maintaining the balance between sugar, fat, and energy in the body; in
the regulation of mitochondrial biosynthesis; and in other biological processes.2–4 In recent years, several studies have shown that the low
PGC-1α expression is probably involved in malignant progression in a wide
variety of tumor tissues, including breast cancer, colon cancer, and ovarian
cancer.5–7 However, the study by Cormio et al and
our previous study have shown that the expression of PGC-1α is elevated in
endometrial carcinoma, and our preliminary study found that its expression is closely
related to the clinical stage, depth of muscular infiltration, and lymph-node metastasis
of the cancer.8,9Apoptosis is a type of programmed cell death. There are two commonly described pathways
of apoptosis: the intrinsic cell death pathway (the mitochondria-initiated pathway) and
the extrinsic cell death pathway (the cell death receptor pathway).10 Mitochondria-dependent apoptosis is regulated by a
group of proteins belonging to the Bcl-2 family, which can be divided into two major
groups, the proapoptotic proteins (eg, Bax) and the antiapoptotic proteins (eg, Bcl-2).
The balance between the pro- and antiapoptotic proteins determines whether apoptosis is
initiated. Studies have shown that without apoptotic stress, Bcl-2 forms heterodimers
with Bax to maintain the outer mitochondrial membrane integrity and block mitochondrial
apoptosis. In the presence of apoptotic stimuli, the expression of proapoptotic protein
Bax increased, following which they bind to prosurvival Bcl-2 proteins to release them
from inhibition. Free Bax forms oligomers, leading to cytochrome c release from the
intermembrane space of mitochondria to the cytoplasm. The released cytochrome c
activates the caspase cascade to induce apoptosis.11In this study, the role of PGC-1α in the apoptosis of endometrial carcinoma
cells was investigated experimentally. We first observed that the specific
downregulation of PGC-1α increased the apoptosis of HEC-1A cells. Our data
showed that the downregulation of PGC-1α promoted cell apoptosis through the
mitochondrial apoptotic pathway by reducing the expression of Bcl-2 and increasing the
expression of Bax. Therefore, we suggest that PGC-1α plays an important role in
cell apoptosis in endometrial cancer. Our results provided a molecular basis for further
investigation of the mechanism of cell apoptosis in endometrial cancer.
Materials and methods
Materials
DharmaFECT transfection reagent was purchased from Thermo Fisher Scientific (Waltham,
MA, USA). TRIzol Reagent was also from Thermo Fisher Scientific. The primary antibody
against humanPGC-1α was obtained from Santa Cruz Biotechnology Inc. (Dallas,
TX, USA), and the primary antibodies against humanBcl-2 and Bax were obtained from
Zhongshan Biotechnology Co. (Beijing, People’s Republic of China). Cell Cycle
and Apoptosis Analysis Kits, Annexin V-FITC Apoptosis Detection Kit, and
Mitochondrial Membrane Potential Assay Kit with JC-1 were all purchased from Beyotime
Biotechnology Co. (Shanghai, People’s Republic of China). Fetal bovine serum
was from HyClone (Logan, UT, USA).
Cell line and culture
The humanendometrial cancer cell line HEC-1A was purchased from the Shanghai
Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai,
People’s Republic of China). The cells were cultured as adherent monolayers
in McCoy’s 5A medium (Thermo Fisher Scientific) containing 10% fetal bovine
serum at 37°C under 5% CO2 in a saturated humidified incubator.
This study protocol was approved by the Ethics Committee of China Medical
University.
Transfection
Three small interfering RNAs (siRNAs) targeting different sites in the humanPGC-1α mRNA (GenBank accession no NM_013261.3) were designed and synthesized
by GenePharma Co., Ltd (Jiangsu, People’s Republic of China) to knock down
PGC-1α expression, and a control siRNA that did not target PGC-1α
mRNA was synthesized as the negative control (NC). Normal HEC-1A cells were used as
the untreated control. All the siRNAs are listed in Table 1.
Table 1
siRNA sequences used in this study
Name
siRNA sequence
siRNA-1
Sense:
5′-GUCCGAGUCACAACACUUATT-3′
Antisense:
5′-UAAGUGUUGUGACUGCGACTT-3′
siRNA-2
Sense:
5′-GGACAGUGAUUUCAGUAAUTT-3′
Antisense:
5′-AUUACUGAAAUCACUGUCCTT-3′
siRNA-3
Sense:
5′-CACCACUCCUCCUCAUAAATT-3′
Antisense:
5′-UUUAUGAGGAGGAGUGGUGTT-3′
NC
Sense:
5′-UUCUCCGAACGUGUCACGUTT-3′
Antisense:
5′-ACGUGACACGUUCGGAGAATT-3′
Abbreviations: siRNA, small interfering RNA; NC, negative
control.
HEC-1A cells (8×105) were seeded in six-well plates and incubated
overnight to allow their full extension and adherence before transfection. The cells
were grown to 70%–90% confluence and then transfected with DharmaFECT
transfection reagent according to the manufacturer’s instructions. siRNA (5
μM, 10 μL) was added to 190 μL of serum-free medium. At the
same time, 5 μL of DharmaFECT transfection reagent was added to 195
μL of serum-free medium. The contents of each tube were then mixed and
incubated for 5 minutes at room temperature. The siRNA was added to the DharmaFECT
transfection reagent and incubated for 20 minutes at room temperature.
Antibiotic-free complete medium (1,600 μL) was then added. Finally, the
culture medium was removed from the wells of the six-well plates and 2 mL of the
appropriate transfection medium was added to each well. The cells were collected for
the further experiments after 72 hours of transfection.
Real-time polymerase chain reaction
Total RNA was isolated from the cells with TRIzol Reagent, according to the
manufacturer's instructions, after 72 hours of transfection. First-strand
complementary DNA was synthesized using the PrimeScript RT reagent Kit (Takara
Holdings, Kyoto, Japan). PGC-1α gene expression was quantified relative to
the endogenous expression level of GAPDH with real-time reverse
transcription polymerase chain reaction (PCR) using the following primer sets: for
PGC-1α, the forward primer was 5′-GACACAACACGGACAGAA-3′ and
the reverse primer was 5′-CACAGGTATAACGGTAGGTAA-3′, and for GAPDH,
the forward primer was 5′-GAAGGTGAAGGTCGGAGTC-3′ and the reverse
primer was 5′-GAAGATGGTGATGGGATTTC-3′. An NC containing sterile water
instead of the complementary DNA template was included with each set of PCRs. The PCR
conditions were as follows: stage 1, 1 cycle of initial denaturation for 30 seconds
at 95°C: and stage 2, 40 cycles of denaturation for 3 seconds at
95°C, followed by DNA synthesis for 30 seconds at 60°C. After
amplification, real-time data acquisition and analysis were performed. The relative
quantitative results were calculated using the method.
Western blot
The cells were collected after 72 hours of transfection, washed twice with
phosphate-buffered saline (PBS), incubated in radioimmunoprecipitation assay buffer
(1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
protease inhibitor cocktail) for 30 minutes on ice, and centrifuged at
12,000× g for 15 minutes at 4°C. The total proteins
(30 μg) were resolved with sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes. Next, the
membrane was blocked with 5% nonfat dry milk in Tris-buffered saline with Tween 20,
pH 8.0, and then incubated with primary antibodies (PGC-1α, Bcl-2, Bax, and
β-actin) overnight at 4°C. The appropriate horseradish
peroxidase-conjugated secondary antibodies were used at 1:5,000 for all antibodies.
The proteins were visualized with enhanced chemiluminescence reagent.
The cells were collected after 72 hours of transfection, suspended in PBS, and
counted. The cells (105) were centrifuged at 1,000×
g for 5 minutes, and the supernatant was removed. The cells were
suspended in 195 μL of annexin V-fluorescein isothiocyanate (FITC) binding
buffer and 5 μL of annexin V-FITC and incubated in the dark at room
temperature for 20 minutes. They were then centrifuged at 1,000×
g for 5 minutes and resuspended in 190 μL of binding
buffer and 10 μL of the propidium iodide (PI) working solution. Cell
apoptosis was analyzed with a flow cytometer (BD FACSAria, San Jose, CA, USA).
Cell-cycle analysis
The cells were collected after 72 hours of transfection, centrifuged at
1,000× g for 5 minutes, and suspended in ice-cold PBS. The
cells were again centrifuged at 1,000× g for 5 minutes, and
the supernatant was removed. The cells were then fixed in 70% ice-cold ethanol at
4°C overnight. After centrifugation (1,000× g, 5
minutes), the cells were diluted with PBS and recentrifuged. The cells for each
condition were then incubated with 500 μL of PI staining buffer at
37°C for 30 minutes in the dark. The cell cycles were analyzed with a flow
cytometer at 488 nm.
Measurement of mitochondrial membrane potential
Changes in the mitochondrial membrane potential
(Δψm) were assessed with a
Mitochondrial Membrane Potential Assay Kit with JC-1. The cells were collected after
72 hours of transfection, washed with PBS, and incubated with a medium containing 20
μg/mL of JC-1 at 37°C for 20 minutes. The cells were washed twice
with JC-1 binding buffer, suspended in 500 μL of JC-1 binding buffer, and
then analyzed with flow cytometry.
Statistical analysis
Data are presented as mean ± SD values. Statistical comparisons were made
with one-way analysis of variance and t-tests. Statistical
significance was defined as P-values <0.05. All statistical
analyses were performed with the SPSS Version 17.0 software (SPSS Inc., Chicago, IL,
USA).
Results
siRNA-2 downregulated PGC-1α expression in HEC-1A cells
After 72 hours of transfection, real-time PCR was used to detect the expression of
PGC-1α mRNA in the HEC-1A cells. The three siRNAs downregulated the
expression of PGC-1α mRNA in the HEC-1A cells, but siRNA-2 significantly
reduced the expression of PGC-1α (Figure 1A). To confirm the interference of PGC-1α protein
expression by siRNA-2, PGC-1α expression in the HEC-1A cells was examined
with Western blot. PGC-1α protein expression was reduced after 72 hours of
transfection with siRNA-2 (Figure
1B). The same result could be seen in humanendometrial cancer RL95-2 cells in
Figure S1A.
All these results confirmed that siRNA-2 was an effective interferent that could be
used for further experiments.
Figure 1
PGC-1α expression in the HEC-1A cells after 72 hours of transfection with
siRNAs.
Notes: (A) Real-time PCR analysis showed that all three
siRNAs reduced the expression of PGC-1α after 72 hours of transfection
compared with that in the NC siRNA-treated cells or in the untreated HEC-1A cells.
siRNA-2 significantly reduced the expression of PGC-1α. (B)
Western blot analysis showed that siRNA-2 reduced the expression of PGC-1α
after 72 hours of transfection compared with that in the siRNA-transfected cells
or in the untreated HEC-1A cells. Data are the mean ± SD values of three
independent experiments. *P<0.05 (ANOVA).
Knockdown of PGC-1α-induced apoptosis in HEC-1A cells
We evaluated the apoptotic effects of PGC-1α in the endometrial cancerHEC-1A
cells using an annexin V-FITC/PI staining assay. The percentage of apoptotic cells
among the HEC-1A cells transfected with siRNA-2 (9.87%±4.10%) was greater
than those in the NC-treated (2.73%±1.00%) and untreated cells
(1.07%±0.38%; Figure 2A and
B). The same result could be seen in the RL95-2 cells in Figure S1B. These
results suggest that PGC-1α influences apoptosis in the HEC-1A cells.
Figure 2
Effects of PGC-1α knockdown on apoptosis of HEC-1A cells.
Notes: (A) Cell apoptosis was detected with annexin
V-FITC/PI double staining and flow cytometry. (B) Values (intensity
of fluorescent positive cells during early apoptotic events) are given as mean
± SD of triplicate experiments. *P<0.05
compared with the NC-treated and untreated control cells (ANOVA).
Knockdown of PGC-1α induced HEC-1A cell apoptosis by changing the
mitochondrial membrane potential
To assess the effects of PGC-1α knockdown on the cell cycle, we analyzed the
phases of the cell cycle after 72 hours of transfection of cells with siRNA-2.
Comparing the NC-treated and untreated cells, there was no obvious change in the cell
cycle after 72 hours of transfection of cells with siRNA-2 (Figure 3A and B). These results indicate that the
downregulation of PGC-1α expression does not alter the cell cycle in the
HEC-1A cells. The same result could be seen in the RL95-2 cells in Figure S1C.
Therefore, PGC-1α may influence the apoptosis of HEC-1A cells without
altering the cell cycle.
Figure 3
Effects of PGC-1α knockdown on the cell cycle in the HEC-1A cells.
Notes: (A) cell-cycle distribution in the HEC-1A cells
after 72 hours of transfection with siRNA-2 or NC, or in the untreated control
cells. (B) Percentages of cells in the G1, S, and G2/M phases of the
cell cycle (n=3). Values are given as the mean ± SD of triplicate
experiments. P>0.05 (ANOVA).
The loss of mitochondrial membrane potential is recognized as an early event in cells
undergoing mitochondria-mediated apoptosis. We investigated the mitochondrial
membrane potential with the fluorescent probe JC-1 and a flow cytometer. Our results
show that the percentage of cells displaying green fluorescence increased
significantly after 72 hours of transfection with siRNA-2 (25.9%±3.96%)
compared with the percentages among the NC-treated (11.25%±1.77%) and
untreated cells (13.85%±3.04%; Figure 4A and B). These results suggest that the knockdown of
PGC-1α reduces the mitochondrial membrane potential. Therefore,
PGC-1α may affect the apoptosis of HEC-1A cells via the mitochondria-mediated
pathway. The same result could be seen in the RL95-2 cells in Figure S1D.
Figure 4
Effects of PGC-1α knockdown on the mitochondrial membrane potential in the
HEC-1A cells.
Notes: (A) Cells were stained with JC-1 and analyzed
with flow cytometry after 72 hours of transfection with siRNA-2 or NC siRNA.
siRNA-2 treatment increased the number of cells with low
Δψm. (B)
Quantification of the results showed that siRNA-2 treatment increased the number
of cells with low Δψm. Results are
shown as the mean ± SD values of three independent experiments.
*P<0.05 compared with the NC-treated and
untreated control cells (ANOVA).
Knockdown of PGC-1α changed the expression of Bcl-2 and Bax
The protein regulators Bcl-2 and Bax belong to the Bcl-2 family, which is known to
contain apoptosis-regulatory factors. Bcl-2 inhibits cell apoptosis, whereas the
overexpression of Bax promotes apoptosis. The interactions between the members of the
Bcl-2 family play an important role in the mitochondria-mediated apoptotic pathway.
To determine the effects of PGC-1α on the apoptosis of HEC-1A cells, the
expression of the apoptosis-related proteins Bax and Bcl-2 was analyzed with Western
blot. The expression of Bcl-2 decreased, and the expression of Bax increased after 72
hours of transfection with siRNA-2 (Figure
5A–C) compared with their expression in the NC-treated and
untreated control cells. These results suggest that the knockdown of PGC-1α
affects cell apoptosis through the mitochondria-mediated pathway by reducing the
expression of Bcl-2 and increasing the expression of Bax. The same result could be
seen in the RL95-2 cells (Figure S2A–C).
Figure 5
Knockdown of PGC-1α increased Bax expression and reduced Bcl-2 expression
in the HEC-1A cells.
Notes: (A–C) Western blot ratio analysis of Bax
and β-actin, Bcl-2 and β-actin, and Bax and Bcl-2 is shown. In the
siRNA-2 group, Bcl-2 expression was lower than in the NC-treated and untreated
cells, whereas Bax expression was higher. Results are shown as the mean ±
SD values of three independent experiments.
*P<0.05 compared with the NC-treated and
untreated control cells (ANOVA).
PGC-1α is a member of the peroxisome proliferator-activated receptor gamma
coactivator-1 family, which has three members: PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator-1 beta, and PGC-1-related
coactivator.12 PGC-1α was
first identified in the mouse brown adipose tissue with the yeast two-hybrid technology
by Puigserver in 1998.13 It plays an
important role in the processes of mitochondrial biosynthesis, glucose transport, and
cell apoptosis. In recent years, studies have shown that PGC-1α is involved in
the development of some malignant tumors. Its expression is lower in some cancers than
in normal tissues, including colon, breast, and ovarian cancer.5–7 However, its expression in other cancers is higher than in normal tissues.
The study by Cormio et al and our previous study suggested that PGC-1α
expression is higher in endometrial cancer tissues than in normal endometrial
tissues.8,9The annexin V-FITC/PI staining assay was always used to evaluate the apoptotic effects.
Several studies have suggested that the lower left quadrant represents the surviving
cells, the lower right quadrant represents the early apoptotic cells, the upper right
quadrant represents the necrotic or postapoptotic cells, and the upper left quadrant
represents the allowed detection error by using the annexin V-FITC/PI staining
assay.14,15 In this study, we found that the downregulation of
PGC-1α expression induced early apoptosis of HEC-1A cells. It is well known that
anaerobic glycolysis is the main way through which adenosine triphosphate is provided to
cancer cells, even under oxygen-sufficient conditions. This phenomenon is known as the
Warburg effect, and it is probably attributable to the damaged mitochondrial function
within the cancer cells. Several studies have speculated that PGC-1α expression
is lower in some cancer tissues, reducing the generation of mitochondria and increasing
glycolysis, which are consistent with the Warburg effect.5–7 However, in recent years, studies have indicated that mitochondrial
function is required for transformation and tumor growth.16–18 A study by Bhalla et al has shown that loss of PGC-1α protects
against carcinogenesis and that PGC1α coordinately regulates mitochondrial and
fatty acid metabolism to promote tumor growth.19 Therefore, we speculate that the downregulation of PGC-1α
expression induces HEC-1A cell apoptosis by regulating some mitochondrial functions.It is well known that blocking the cell cycle induces cell apoptosis. In this study, we
found that the downregulation of PGC-1α expression did not induce cell apoptosis
by affecting the cell cycle. Two separate pathways leading to cell apoptosis have been
clearly documented: the extrinsic and intrinsic pathways. The intrinsic pathway is
mediated by the mitochondria.20 A
decline in the mitochondrial membrane potential is regarded as an important landmark in
early cell apoptosis. In this study, the mitochondrial membrane potential was lower
after the cells were transfected with siRNA-2 than in the NC-treated or untreated cells,
which suggests that the downregulation of PGC-1α expression induces cell
apoptosis via the mitochondria-mediated pathway in the HEC-1A cells.In recent years, several studies have suggested that the permeabilization of the
mitochondrial outer membrane plays an important role in mitochondria-mediated cell
apoptosis. The interaction between members of the Bcl-2 family regulates mitochondrial
outer membrane permeabilization and thus induces cell apoptosis.11,21
In this study, we found that the expression of the prosurvival protein Bcl-2 was lower
and that of the proapoptotic protein Bax was higher after the downregulation of
PGC-1α expression in the HEC-1A cells. This indicates that the downregulation of
PGC-1α induces cell apoptosis by affecting the expression of Bcl-2 and Bax and
changing the permeability of the mitochondrial membrane.
Conclusion
The downregulation of PGC-1α expression may induce HEC-1A cell apoptosis through
the mitochondria-mediated pathway by regulating the expression of Bcl-2 and Bax. We
infer that PGC-1α plays a dual role in the development of cancers.
PGC-1α stands at the crossroads of many pathways as the control of mitochondria
biogenesis, tumor cell energy, and protection of tumor cells against apoptosis via a
mitochondrial pathway, representing a good target for therapeutic intervention. However,
the specific regulatory mechanism is still unclear and will be investigated in our
future studies.PGC-1α expression in RL95-2 cells after their transfection with siRNA-2,
and effects of PGC-1α knockdown on apoptosis, cell cycle and the
mitochondrial membrane potential in RL95-2 cells. (A) Western
blotting analysis showed that siRNA-2 reduced the expression of PGC-1α 72
h after transfection compared with that in cells transfected with the negative
control siRNA or in untreated RL95-2 cells of three independent experiments.
(B) Cell apoptosis was detected with annexin V-FITC/PI double
staining and flow cytometry in RL95-2 cells. Values (intensity of fluorescent
positive cells during early apoptotic events). (C) Cell-cycle
distribution in RL95-2 cells 72 h after transfection with siRNA-2 or NC, or in
untreated control cells. Percentages of cells in G1, S, and G2/M phases of the
cell cycle. (D) Cells were stained with JC-1 and analyzed with flow
cytometry 72 h after transfection with siRNA-2 or the negative control siRNA.
siRNA-2 treatment increased the number of cells with low Δψm.
Quantification of the results showed that siRNA-2 treatment increased the number
of cells with low Δψm. We analyzed three independent experiments
which compared with the NC-treated and untreated control cells.Notes: Data are the means ± SD of three independent
experiments comparing treatment and untreated control cells.
*P<0.05 (ANOVA).Abbreviations: PGC-1α, peroxisome proliferator-activated
receptor gamma coactivator-1 alpha; NC, negative control; siRNA, small interfering
RNA; PI, propidium iodide; AV-FITC, Annexin V-fluorescein isothiocyanate; MMP,
mitochondrial membrane potential.Knockdown of PGC-1α increased Bax expression and reduced Bcl-2 expression
in RL95-2 cells. (A, B and C) Western blot
ratio analysis of Bax and β-actin, Bcl-2 and β-actin, and Bax and
Bcl-2. In the siRNA-2 group, Bcl-2 expression was lower than in the NC-treated and
untreated cells, whereas Bax expression was higher.Notes: Results are shown as the means ± SD of three
independent experiments. *P<0.05 compared with
the NC-treated and the untreated control cells (ANOVA).
Authors: Yan Zhang; Yi Ba; Chang Liu; Guoxun Sun; Li Ding; Songyuan Gao; Jihui Hao; Zhentao Yu; Junfeng Zhang; Ke Zen; Zhongsheng Tong; Yang Xiang; Chen-Yu Zhang Journal: Cell Res Date: 2007-04 Impact factor: 25.617
Authors: Jonas Feilchenfeldt; Marie Anne Bründler; Claudio Soravia; Martin Tötsch; Christoph A Meier Journal: Cancer Lett Date: 2004-01-08 Impact factor: 8.679
Authors: Valentina Fogal; Adam D Richardson; Priya P Karmali; Immo E Scheffler; Jeffrey W Smith; Erkki Ruoslahti Journal: Mol Cell Biol Date: 2010-01-25 Impact factor: 4.272